SLN360
Silence Therapeutics
[]
silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein at the american heart association 2022 annual meeting $sln 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice